Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A companion study will look at liver biopsy results to confirm these findings from noninvasive tests.
The government-wide effort aims to develop the next generation of COVID-19 treatments to prepare the U.S. to respond to future virus threats
Molnupiravir, previously studied for hepatitis C, might be able to prevent or treat COVID-19 outside of a clinical setting.
The best-performing combo, firsocostat and cilofexor, showed benefits despite missing the main study endpoint.
The study asks whether certain approved therapies or late-stage investigational drugs show promise against COVID-19.
Studies of PPAR agonists have yielded mixed results for people with fatty liver disease.
Four vaccine candidates produced antibody and T-cell immune responses in the first stages of human clinical trials.
Sofosbuvir and daclatasvir were linked to faster recovery and improved survival in studies in Iran.
Dexamethasone reduced mortality by up to a third among severely ill patients who needed supplemental oxygen or ventilators.
FDA grants emergency use authorization, but randomized clinical trials of the antiviral drug show mixed results.
Drugs used for decades to treat malaria may help people with the new coronavirus, but clinical trials are needed.
The protease inhibitor combination did not work significantly better than supportive care, though those treated earlier might benefit.
Lonafarnib and bulevirtide, when used with pegylated interferon, reduced hepatitis delta levels in two studies.
Drugs that have a favorable effect on biomarkers may still play a role in combination therapy, however.
Acting Commissioner Ned Sharpless will return to lead the National Cancer Institute.
Selonsertib did not improve liver fibrosis more than a placebo.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.